Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP-IPV-HB-PRP-T + pneumococcal 13-valent conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination product represents the concomitant administration of a hexavalent vaccine (DTaP-IPV-HB-PRP-T) and a 13-valent pneumococcal conjugate vaccine (PCV13). The hexavalent component, such as Sanofi's Hexaxim or Vaxelis (developed with MSD), provides active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive diseases caused by Haemophilus influenzae type b. The PCV13 component, marketed as Prevenar 13 by Pfizer, targets 13 serotypes of Streptococcus pneumoniae. This combination is primarily used in pediatric immunization schedules to provide broad protection against multiple bacterial and viral pathogens while reducing the total number of injections required during infancy. Clinical trials, such as NCT01177722, have evaluated the safety, immunogenicity, and antibody persistence of these vaccines when administered together in healthy infants.
- Brand names
- Vaxelis
- Other names
- DTaP-IPV-Hep B-PRP-T + PCV13Hexavalent vaccine + PCV13
02
Targets
Fimbrial antigen type 3FHA (Filamentous hemagglutinin)PRN (Pertactin)Diphtheria toxinHBsAg (Hepatitis B surface antigen)CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on DTaP-IPV-HB-PRP-T + pneumococcal 13-valent conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP-IPV-HB-PRP-T + pneumococcal 13-valent conjugate vaccine.